Zetomipzomib (KZR-616) demonstrates anti-inflammatory and immunomodulatory potential in patients with active lupus with or without lupus nephritis: Results from the open-label Phase 1b/2 MISSION study (LUPUS-KCR 2023) - May 20, 2023 - Abstract #LO-017; Pres time: May 19, 2023; 10:30 AM - 12:00 PM; Location: Auditorium; No abstract available
Clinical • Immunomodulating • P1/2 data • Glomerulonephritis • Immune Modulation • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|